These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1671646)

  • 1. Plasma homovanillic acid and prognosis in schizophrenia.
    Baker NJ; Kirch DG; Waldo M; Bell J; Adler LE; Hattox S; Murphy R; Freedman R
    Biol Psychiatry; 1991 Jan; 29(2):192-6. PubMed ID: 1671646
    [No Abstract]   [Full Text] [Related]  

  • 2. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.
    Suzuki E; Kanba S; Nibuya M; Adachi S; Sekiya U; Shintani F; Kinoshita N; Yagi G; Asai M
    Biol Psychiatry; 1994 Nov; 36(10):654-61. PubMed ID: 7880934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma HVA, neuroleptics, and dopaminergic plasticity.
    Dávila R
    Biol Psychiatry; 1989 Jan; 25(1):1-3. PubMed ID: 2563229
    [No Abstract]   [Full Text] [Related]  

  • 5. Measurements of plasma homovanillic acid in schizophrenic patients.
    Davidson M; Kahn RS; Stern RG; Harvey PD; Keefe R; Knott P; Apter S; Webster L; Davis KL
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():521A-522A. PubMed ID: 1354058
    [No Abstract]   [Full Text] [Related]  

  • 6. Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited.
    Volavka J; Douyon R; Convit A; Czobor P; Cooper TB
    Arch Gen Psychiatry; 1992 Dec; 49(12):999-1000. PubMed ID: 1449388
    [No Abstract]   [Full Text] [Related]  

  • 7. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
    Khan RS; Amin F; Powchik P; Knott P; Goldstein M; Apter S; Kerman B; Jaff S; Davidson M
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):879-84. PubMed ID: 1980541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
    Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients.
    Szymanski S; Lieberman JA; Alvir JM; Mayerhoff D; Loebel A; Geisler S; Chakos M; Koreen A; Jody D; Kane J
    Am J Psychiatry; 1995 May; 152(5):698-703. PubMed ID: 7726309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
    Davila R; Gonzalez MA; Zumarraga M; Andia I; Guimon J; Silva RR; Friedhoff AJ
    Biol Psychiatry; 1995 Aug; 38(4):267-9. PubMed ID: 8547450
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of -141C Ins/Del Polymorphism in DRD2 Gene on Clinical Symptoms and Plasma Homovanillic Acid Levels in the Treatment of Schizophrenia With Aripiprazole.
    Miura I; Kanno-Nozaki K; Hino M; Horikoshi S; Ota T; Mashiko H; Niwa S; Yabe H
    J Clin Psychopharmacol; 2015 Jun; 35(3):333-4. PubMed ID: 25871573
    [No Abstract]   [Full Text] [Related]  

  • 12. Diurnal variation in plasma homovanillic acid in patients with schizophrenia and healthy controls.
    Duncan E; Bollini AM; Sanfilipo M; Wieland S; Angrist B; Cooper TB; Rotrosen J
    Schizophr Res; 2006 Jan; 81(2-3):323-6. PubMed ID: 16181774
    [No Abstract]   [Full Text] [Related]  

  • 13. Predicting haloperidol treatment response in chronic schizophrenia.
    van Kammen DP; Kelley ME; Yao JK; Gilbertson MW; Gurklis JA; Inosaka T; Saito H; Peters JL; Sato M
    Psychiatry Res; 1996 Aug; 64(1):47-58. PubMed ID: 8888364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
    Dávila R; Zumárraga M; Basterreche N; Arrúe A; Anguiano JB
    Psychiatry Res; 2007 May; 151(1-2):163-8. PubMed ID: 17434602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia.
    Koshikawa H; Suzuki E; Kanba S; Nibuya M; Ishizuki T; Kohno H; Kinoshita N; Shintani F; Yagi G; Nakaki T
    Yakubutsu Seishin Kodo; 1991 Feb; 11(1):79-81. PubMed ID: 1679276
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls.
    Davidson M; Davis KL
    Arch Gen Psychiatry; 1988 Jun; 45(6):561-3. PubMed ID: 3377642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
    Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
    Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of cyclicity of the plasma dopamine metabolite, homovanillic acid, in neuroleptic treated schizophrenic patients.
    Davila R; Zumarraga M; Andia I; Friedhoff AJ
    Life Sci; 1989; 44(16):1117-21. PubMed ID: 2565009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of plasma HVA and treatment response in a large series of patients with schizophrenia.
    Davila R
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():519A-520A. PubMed ID: 1354057
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.